Salve, We're Tanner
Improving lives for
20 years by enabling
access to medicine.
Who We Are
Our Mission to Improve Lives
Estimates show that nearly 2 billion people around the world lack access to essential medicines. At Tanner Pharma Group , we’re advocates for the lifesaving power of medicine. But beyond this, we understand the importance of having access to it. Through our global partner network, determined and resourceful team, decades of global distribution experience and passion for health equity, we’ve been able to positively impact thousands of lives through access to medicine. And our journey is only just beginning. Learn more →
Join the Tanner journey. Let’s find ways to improve patient lives, together.
YES, WE CAN
Our goal is simple, to improve lives by increasing access to medicines around the world.
We deliver solutions for organizations in the global healthcare network, removing barriers and implementing programs so they can:
- Provide access to medicines for patients in need
- Demonstrate the value of new medications
- Enable better health
YES, WE WILL
Our commitment is unwavering.
We relentlessly pursue and deliver the best solutions to enable access, no matter how challenging the situation. We are resourceful and creative and always going the extra mile.
YES, WE DID
The Challenge:
Reduce the risk of infection in leukemia patients.
LEUKINE®, approved by the US FDA in 1991, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection.
In 2018, Partner Therapeutics, Inc. (PTx) acquired the global rights to develop, manufacture, and commercialize Leukine ® (sargramostim) from Sanofi. As a small company, Ptx did not have the internal resources to handle international requests for the drug and didn’t know how they could successfully support patients outside the US, in full regulatory compliance, even though the product was not registered in other geographies.
Read More
YES, WE DID
The Challenge:
Provide free cancer treatment to patients around the world
The Max Foundation is a global non-profit organization focused on increasing the access to treatment, care and support for people living with cancer around the world. In 2017 the Foundation sought to put in place The Max Access Solutions program, a patient-centric care model for delivering free cancer treatment to those in need. The Foundation wanted to be able to offer its patients targeted treatment using a portfolio of oncology medicines from multiple pharmaceutical companies. They sought a partner to handle the distribution, quality assurance and regulatory activities to safely and securely store, handle and deliver the medicines to their patients. After evaluating options for a partner to manage the distribution, Tanner was selected.
Read More
YES, WE DID
The Challenge:
Uninterrupted distribution to patients in Latin America
A major pharmaceutical company divested a mature pipeline asset to a medium size pharma company that did not have a presence in Latin America, but wanted to continue distribution of the product.
Read More
YES, WE DID
The Challenge:
Assuring continuity during a global pandemic
A leading clinical-stage biotechnology company required packs of a comparator to conduct a Phase III trial for their leading asset. They required the stock in a single lot, and because of the ongoing COVID-19 pandemic, wanted stock with a long shelf life and additional assurances regarding the supply chain to minimize lead times and the chance of unexpected manufacturer disruptions.
Read MoreTESTIMONIAL
Tanner Pharma Group is truly an example of what it means to put humanity at the center of their business. This was not just words on a page or some empty mission statement, it’s compassion in action!
They are a prime example on how Pharma should be running their business and focusing their motivation.
Joshua Frase FoundationPROVIDING ACCESS TO
120+
countries with the help of our non-profit collaborators:
RECENT NEWS & EVENTS
-
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership with Agenus
Read original publication on Business Wire: click here Charlotte, N.C., and Lexington, Mass. – Tanner Pharma, a global provider of specialty medicine access solutions, today announced a collaboration with Agenus, a leading immuno-oncology company, to provide expanded access to botensilimab (BOT) and balstilimab (BAL). Through a Named Patient Program (NPP), this initiative offers patients with…
Read More -
Tanner Pharma Directors to Attend Key International Healthcare Conferences in 2025
Directors from Tanner Pharma Group will attend several international healthcare conferences in the coming weeks. Connect with our team members directly or via conference platforms to schedule meetings. We look forward to meeting with you. JPM Healthcare Conference 13-16 January | San Francisco, CA USA Arab Health 27-30 January | Dubai SCOPE Summit 3-6 February…
Read More -
Tanner Pharma Group Recognized by the Charlotte Business Journal as One of the Best Places to Work
We are pleased to share that Tanner Pharma Group has been recognized as one of the Best Places to Work by the Charlotte Business Journal. This honor reflects our dedication to our employees and the communities we serve. Here’s a closer look at what we feel makes Tanner Pharma Group a remarkable workplace: Employee Engagement…
Read More